应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BTAI Bioxcel Therapeutics Inc.
休市中 05-17 16:00:00 EDT
2.07
-0.02
-0.96%
盘后
2.10
+0.03
+1.45%
18:29 EDT
最高
2.19
最低
2.06
成交量
89.46万
今开
2.10
昨收
2.09
日振幅
6.22%
总市值
7,769万
流通市值
5,164万
总股本
3,753万
成交额
188.41万
换手率
3.59%
流通股本
2,495万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Bioxcel Therapeutics, Inc.2024财年第一财季实现净利润-26.79百万美元,同比增加49.26%
自选股智能写手 · 05-18 00:24
Bioxcel Therapeutics, Inc.2024财年第一财季实现净利润-26.79百万美元,同比增加49.26%
BioXcel Therapeutics Inc 预计每股亏损70美分 - 财报前瞻
Reuters · 05-08
BioXcel Therapeutics Inc 预计每股亏损70美分 - 财报前瞻
HC Wainwright & Co.:重申BioXcel Therapeutics(BTAI.US)评级,由买入调整至买入评级, 目标价10.00美元。
智通财经 · 04-23
HC Wainwright & Co.:重申BioXcel Therapeutics(BTAI.US)评级,由买入调整至买入评级, 目标价10.00美元。
Bioxcel Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报2.68美元
自选股智能写手 · 04-19
Bioxcel Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报2.68美元
Bioxcel Therapeutics, Inc.盘中异动 大幅上涨5.32%
自选股智能写手 · 04-12
Bioxcel Therapeutics, Inc.盘中异动 大幅上涨5.32%
嗡嗡声--美国股票走势-Diamondback、Rivian Automotive、BioXcel Therapeutics
Reuters · 02-12
嗡嗡声--美国股票走势-Diamondback、Rivian Automotive、BioXcel Therapeutics
公司概况
公司名称:
Bioxcel Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Bioxcel Therapeutics, Inc.于2017年3月29日成为特拉华州公司,为BioXcel的全资附属公司。 BioXcel Therapeutics,Inc.或BTI是一家临床阶段的生物制药公司,专注于药物开发,利用新型人工智能或人工智能识别神经科学和免疫肿瘤学领域的下一波药物。他们的药物再创新方法利用现有批准的药物或经临床验证的产品候选药物以及大数据和专有机器学习算法来确定新的治疗指标。他们的两个最先进的临床开发项目是BXCL501,一种a2a肾上腺素能受体激动剂右美托咪定或Dex的舌下薄膜制剂,用于急性治疗由神经和精神疾病引起的激动,和BXCL701,一种用于治疗罕见形式的前列腺癌和胰腺癌。他们在2017年12月开始使用Dex在轻度可能AD中的IV制剂的1b期药代动力学/药效学或PK / PD安全性研究,并且他们计划在精神分裂症患者中使用Dex的IV制剂开始1b期药代动力学/药效学安全性研究,他们期望在2018年下半年报告这两项研究的数据。他们还打算在2018年开始两项计划的第二阶段概念证明或PoC开放标签临床试验。他们预计,到2018年底,计划在BXCL501计划的阶段2 PoC开放标签临床试验中提供的数据读数将可用。
发行价格:
--
{"stockData":{"symbol":"BTAI","market":"US","secType":"STK","nameCN":"Bioxcel Therapeutics Inc.","latestPrice":2.07,"timestamp":1715976000000,"preClose":2.09,"halted":0,"volume":894560,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.07,"latestTime":"18:29 EDT","volume":6058,"amount":12564.395,"timestamp":1715984982501},"delay":0,"floatShares":24946233,"shares":37530821,"eps":-5.154519,"marketStatus":"休市中","marketStatusCode":7,"change":-0.02,"latestTime":"05-17 16:00:00 EDT","open":2.1,"high":2.19,"low":2.06,"amount":1884080.67496,"amplitude":0.062201,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.154519,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"listingDate":1520485200000,"adjPreClose":2.09,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":2.09,"latestTime":"09:27 EDT","volume":91,"amount":190.56000600000002,"timestamp":1715952470040},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.07,"latestTime":"18:29 EDT","volume":6058,"amount":12564.395,"timestamp":1715984982501},"volumeRatio":1.6413908817628196},"requestUrl":"/m/hq/s/BTAI/wiki","defaultTab":"wiki","newsList":[{"id":"2436276946","title":"Bioxcel Therapeutics, Inc.2024财年第一财季实现净利润-26.79百万美元,同比增加49.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436276946","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436276946?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:24","pubTimestamp":1715963076,"startTime":"0","endTime":"0","summary":"3月31日,Bioxcel Therapeutics, Inc.公布财报,公告显示公司2024财年第一财季净利润为-26.79百万美元,同比增加49.26%;其中营业收入为582000.00美元,同比增加182.52%,每股基本收益为-0.87美元。机构评级:截至2024年3月31日,当前有5家机构对Bioxcel Therapeutics, Inc.目标价做出预测,其中目标均价为6.30美元,其中最低目标价为3.50美元,最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800244887750d11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800244887750d11&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433780273","title":"BioXcel Therapeutics Inc 预计每股亏损70美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433780273","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433780273?lang=zh_cn&edition=full","pubTime":"2024-05-08 00:59","pubTimestamp":1715101156,"startTime":"0","endTime":"0","summary":" * BioXcel Therapeutics Inc 将于5月9日公布截至2024年3月31日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,5位分析师的平均预期显示,这家总部位于康涅狄格州纽黑文的公司的营收预计将从一年前的20.6万美元增至46.4万美元,增幅为125.2%。* LSEG 分析师对 BioXcel Therapeutics Inc 的平均预期是每股亏损 70 美分。* 华尔街对 BioXcel Therapeutics Inc 的 12 个月目标价中位数为 7.00 美元,高于其上次收盘价 2.51 美元。5月7日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429670201","title":"HC Wainwright & Co.:重申BioXcel Therapeutics(BTAI.US)评级,由买入调整至买入评级, 目标价10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429670201","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429670201?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:36","pubTimestamp":1713868586,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申BioXcel Therapeutics(BTAI.US)评级,由买入调整至买入评级, 目标价10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042318362887a5c895&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042318362887a5c895&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428665777","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报2.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428665777","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428665777?lang=zh_cn&edition=full","pubTime":"2024-04-19 22:17","pubTimestamp":1713536262,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日22时17分,Bioxcel Therapeutics, Inc.股票出现波动,股价快速拉升5.10%。截至发稿,该股报2.68美元/股,成交量12.5851万股,换手率0.41%,振幅5.80%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.76%。其相关个股中,Lexaria Bioscience Corp C/Wts 14/01/2026 、Chromocell Therapeutics Corporation、艾吉纳斯涨幅较大,Bio-Path Holdings, Inc.、Kintara Therapeutics, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为177.17%、9.50%、7.41%,振幅较大的相关个股有Chromocell Therapeutics Corporation、Portage Biotech Inc.、Humacyte Inc C/Wts 27/08/2026 ,振幅分别为34.28%、27.12%、23.85%。Bioxcel Therapeutics, Inc.公司简介:BioXcel Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192217427a541f73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404192217427a541f73&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426994612","title":"Bioxcel Therapeutics, Inc.盘中异动 大幅上涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426994612","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426994612?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:46","pubTimestamp":1712861171,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日02时46分,Bioxcel Therapeutics, Inc.股票出现波动,股价急速拉升5.32%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.01%。其相关个股中,Rallybio Corporation、Eliem Therapeutics, Inc、Geovax Labs Inc C/Wts 29/09/2025涨幅较大,Adial Pharmaceuticals, Inc、Aptevo Therapeutics Inc.、Scisparc Ltd.较为活跃,换手率分别为823.84%、622.11%、523.28%,振幅较大的相关个股有Veru Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Rallybio Corporation,振幅分别为53.23%、52.42%、50.92%。Bioxcel Therapeutics, Inc.公司简介:BioXcel Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120246127a5231f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120246127a5231f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2410405668","title":"嗡嗡声--美国股票走势-Diamondback、Rivian Automotive、BioXcel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2410405668","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2410405668?lang=zh_cn&edition=full","pubTime":"2024-02-12 22:23","pubTimestamp":1707747784,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月12日 - 继前一周强劲收盘后,周一美国股指期货表现低迷,市场关注一系列经济数据,这些数据可能会消除降息前景的一些不确定性。美东时间9:01,道指电子盘 下跌0.10%,报38,710点。标准普尔500指数小型股 下跌0.03%,报5,042.25点;纳斯达克100指数小型股 下跌0.05%,报18,029.75点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioxceltherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0096},{"period":"1month","weight":-0.2008},{"period":"3month","weight":-0.4103},{"period":"6month","weight":-0.4988},{"period":"1year","weight":-0.922},{"period":"ytd","weight":-0.2983}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bioxcel Therapeutics, Inc.于2017年3月29日成为特拉华州公司,为BioXcel的全资附属公司。 BioXcel Therapeutics,Inc.或BTI是一家临床阶段的生物制药公司,专注于药物开发,利用新型人工智能或人工智能识别神经科学和免疫肿瘤学领域的下一波药物。他们的药物再创新方法利用现有批准的药物或经临床验证的产品候选药物以及大数据和专有机器学习算法来确定新的治疗指标。他们的两个最先进的临床开发项目是BXCL501,一种a2a肾上腺素能受体激动剂右美托咪定或Dex的舌下薄膜制剂,用于急性治疗由神经和精神疾病引起的激动,和BXCL701,一种用于治疗罕见形式的前列腺癌和胰腺癌。他们在2017年12月开始使用Dex在轻度可能AD中的IV制剂的1b期药代动力学/药效学或PK / PD安全性研究,并且他们计划在精神分裂症患者中使用Dex的IV制剂开始1b期药代动力学/药效学安全性研究,他们期望在2018年下半年报告这两项研究的数据。他们还打算在2018年开始两项计划的第二阶段概念证明或PoC开放标签临床试验。他们预计,到2018年底,计划在BXCL501计划的阶段2 PoC开放标签临床试验中提供的数据读数将可用。","yearOnYearQuotes":[{"month":1,"riseRate":0.833333,"avgChangeRate":0.129318},{"month":2,"riseRate":0.833333,"avgChangeRate":0.365471},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.136546},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.016546},{"month":5,"riseRate":0.428571,"avgChangeRate":0.03818},{"month":6,"riseRate":0.5,"avgChangeRate":-0.103306},{"month":7,"riseRate":0.5,"avgChangeRate":0.058901},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.137488},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.136967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.013323},{"month":11,"riseRate":0.333333,"avgChangeRate":0.076409},{"month":12,"riseRate":0.5,"avgChangeRate":0.192882}],"exchange":"NASDAQ","name":"Bioxcel Therapeutics Inc.","nameEN":"Bioxcel Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bioxcel Therapeutics Inc.,BTAI,Bioxcel Therapeutics Inc.股票,Bioxcel Therapeutics Inc.股票老虎,Bioxcel Therapeutics Inc.股票老虎国际,Bioxcel Therapeutics Inc.行情,Bioxcel Therapeutics Inc.股票行情,Bioxcel Therapeutics Inc.股价,Bioxcel Therapeutics Inc.股市,Bioxcel Therapeutics Inc.股票价格,Bioxcel Therapeutics Inc.股票交易,Bioxcel Therapeutics Inc.股票购买,Bioxcel Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}